Cargando…
Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program
Cancer-associated venous thromboembolism (CAT) guidelines recommend direct oral anticoagulants as alternatives to low-molecular-weight heparin (LMWH) in most patients. This study compared the effectiveness and safety of rivaroxaban versus LMWH for a broad CAT cohort. The cohort study used electronic...
Autores principales: | Caroti, Kimberly Snow, Khorana, Alok A., Becattini, Cecilia, Lee, Agnes Y.Y., Ekbom, Anders, Carrier, Marc, Cohen, Alexander T., Brescia, Christopher, Abdelgawwad, Khaled, Psaroudakis, George, Rivera, Marcela, Schaefer, Bernhard, Brobert, Gunnar, Coleman, Craig I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467381/ https://www.ncbi.nlm.nih.gov/pubmed/37583314 http://dx.doi.org/10.1177/10760296231189282 |
Ejemplares similares
-
Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023) -
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023) -
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020) -
Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
por: Coleman, Craig I., et al.
Publicado: (2021) -
A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial
Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years
por: Coleman, Craig I., et al.
Publicado: (2022)